Antonio Santidrian, Ph.D., serves as Chief Scientific Officer, a position he has held since 2023. In this role, he is responsible for leading all of the company’s research and development initiatives. Antonio is the coinventor of Calidi’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms and leading the development of the innovative Pipeline. Since joining Calidi in 2015, Antonio held several other research and development leadership positions of increasing responsibility enabling him to apply his more than 20 years of experience, in academia and biotech, in anti-cancer translational research to the company’s product development activities.
Prior to joining Calidi, Antonio led translational studies at The Scripps Research Institute for several small molecule and biological drugs to treat breast cancer metastasis. He also worked closely on translational cancer studies for the development of ACADRA to treat Chronic lymphocytic leukemia (CLL) at the University of Barcelona (Spain).
Antonio received degrees in pharmacy from the University of Barcelona, and his Ph.D. in biomedicine, specializing in anti-cancer therapies, from the University of Barcelona in Barcelona, Spain. He also received fellowships from the August Pi I Sunyer Foundation, the Ministry of Science and Education (Spain), and the Susan G. Komen Breast Cancer Foundation.
